Drug Trial Radar · NCT06738485
Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII Products
Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
62
Actual
Start
Jan 9, 2025
Primary completion
Sep 23, 2026
Study completion Sep 23, 2026
Sponsor
- Lead sponsor
- CSL BehringIndustry
- Sponsor type
- Industry
- First posted
- Dec 17, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- Male only, from 0 days, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
For bridging the available global clinical data of rVIII-SingleChain, with the Chinese population, the aim of this study in China is to investigate the pharmacokinetics (PK) of rVIII-SingleChain after an initial and repeat dose and to assess efficacy and safety during 2 to 3 times weekly prophylaxis treatment with rVIII-SingleChain in male Chinese PTPs with severe hemophilia A (FVIII activity less than \[\<\] 1%).
Conditions
- Congenital Hemophilia A
Interventions
Recombinant single-chain factor VIII (rVIII-SingleChain)Biological
Lyophilized powder for solution for intravenous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incremental Recovery (IR) of rVIII-SingleChainTime frame: Before, and at 30 minutes after the end of, rVIII-SingleChain administration on Day 1
- Maximum Concentration (Cmax) of rVIII-SingleChainTime frame: Before, and up to 72 hours (participants ≥ 12 years ) and 48 hours (participants < 12 years) after rVIII-SingleChain administration on Day 1
- Area Under the Plasma Concentration Time Curve from Time Zero to the Last Measurable Concentration (AUC0-last) of rVIII-SingleChainTime frame: Before, and up to 72 hours (participants ≥ 12 years ) and 48 hours (participants < 12 years) after rVIII-SingleChain administration on Day 1
- Area Under the Plasma Concentration Time Curve from Time Zero to Infinity (AUC0-inf) of rVIII-SingleChainTime frame: Before, and up to 72 hours (participants ≥ 12 years ) and 48 hours (participants < 12 years) after rVIII-SingleChain administration on Day 1
- Half-life (t1/2) of rVIII-SingleChainTime frame: Before, and up to 72 hours (participants ≥ 12 years ) and 48 hours (participants < 12 years) after rVIII-SingleChain administration on Day 1
- Clearance (Cl) of rVIII-SingleChainTime frame: Before, and up to 72 hours (participants ≥ 12 years ) and 48 hours (participants < 12 years) after rVIII-SingleChain administration on Day 1
- Annualized Spontaneous Bleeding Rate (AsBR)Time frame: Up to 29 weeks after rVIII-SingleChain administration
- Number of participants who develop FVIII inhibitorsTime frame: During routine rVIII-SingleChain prophylaxis dosing, up to 29 weeks after rVIII-SingleChain administration.
Locations
20 sites in 1 country. Site status is shown where the registry gives one.
The Second Hospital of Anhui Medical University
Hefei, Anhui, China
Beijing Children's Hospital
Beijing, Beijing Municipality, China
Children's Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China
Fujian Medical University Union Hospital
Fuzhou, Fujian, China
Guangzhou Women and Children's Medical Center
Guangzhou, Guangdong, China
Nanfang Hospital of Southern Medical University
Guangzhou, Guangdong, China
Liuzhou People's Hospital
Liuzhou, Guangxi, China
North China University of Science and Technology Affiliated Hospital
Tangshan, Hebei, China
Hospital of Hematology, Chinese Academy of Medical Sciences
Tianjin, Hebei, China
Henan children's hospital Zhengzhou children's Hospital
Zhengzhou, Henan, China
Hunan Provincial Children's Hospital
Changsha, Hunan, China
Nanjing Children's Hospital
Nanjing, Jiangsu, China
XuZhou Children's Hospital
Xuzhou, Jiangsu, China
Jiangxi Provincial People's Hospital
Nanchang, Jiangxi, China
Quinghai Provincial People's Hospital
Xining, Qinghai, China
Jinan Central Hospital
Jinan, Shandong, China
Qingdao Women and Children's Hospital
Qingdao, Shandong, China
Shanghai Jiaotong University School of Medicine, Ruijin Hospital
Shanghai, Shanghai Municipality, China
The second affiliated hospital of Kunming Medical University
Kunming, Yunan, China
The Children's Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.